Pharmacokinetics, Bioavailability and Safety of PENNSAID® Gel
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
It is anticipated that PENNSAID Gel will minimize systemic exposure versus oral diclofenac
administered twice a day (BID). In addition, PENNSAID Gel should result in greater subject
convenience and compliance with a comparable bioavailability, safety and tolerability profile
to that of the approved PENNSAID solution administered four times a day (QID).